$CDXC
ChromaDex Corp.

2022 Q4 Form 10-Q Financial Statement

#000162828022027803 Filed on November 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $21.00M $17.06M
YoY Change 18.23% -1.42%
Cost Of Revenue $8.980M $6.856M
YoY Change 30.31% 1.87%
Gross Profit $12.02M $10.21M
YoY Change 10.56% -3.51%
Gross Profit Margin 57.23% 59.82%
Selling, General & Admin $12.18M $12.05M
YoY Change -19.54% -34.6%
% of Gross Profit 101.37% 118.04%
Research & Development $1.279M $1.224M
YoY Change 22.39% 22.89%
% of Gross Profit 10.64% 11.99%
Depreciation & Amortization $264.0K $279.0K
YoY Change 0.76% -2.11%
% of Gross Profit 2.2% 2.73%
Operating Expenses $13.46M $13.27M
YoY Change -16.83% -31.65%
Operating Profit -$1.444M -$3.065M
YoY Change -72.84% -65.33%
Interest Expense $26.00K $5.000K
YoY Change -388.89% -66.67%
% of Operating Profit
Other Income/Expense, Net $0.00 $2.085M
YoY Change
Pretax Income -$1.418M -$985.0K
YoY Change -73.37% -88.88%
Income Tax
% Of Pretax Income
Net Earnings -$1.418M -$985.0K
YoY Change -73.37% -88.88%
Net Earnings / Revenue -6.75% -5.77%
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$0.02 -$0.01
COMMON SHARES
Basic Shares Outstanding 74.47M shares 68.34M shares
Diluted Shares Outstanding 68.35M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.24M $13.06M
YoY Change -28.27% -60.54%
Cash & Equivalents $20.30M $13.10M
Short-Term Investments
Other Short-Term Assets $3.167M $4.459M
YoY Change 70.36% 153.06%
Inventory $14.68M $15.64M
Prepaid Expenses
Receivables $8.482M $4.744M
Other Receivables $3.100M $2.400M
Total Short-Term Assets $46.57M $37.90M
YoY Change -4.78% -28.27%
LONG-TERM ASSETS
Property, Plant & Equipment $6.322M $6.505M
YoY Change -14.04% 110.93%
Goodwill
YoY Change
Intangibles $671.0K $714.0K
YoY Change -21.7% -21.37%
Long-Term Investments
YoY Change
Other Assets $497.0K $545.0K
YoY Change -31.26% -5.38%
Total Long-Term Assets $7.490M $7.764M
YoY Change -16.17% 1.93%
TOTAL ASSETS
Total Short-Term Assets $46.57M $37.90M
Total Long-Term Assets $7.490M $7.764M
Total Assets $54.06M $45.67M
YoY Change -6.54% -24.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.679M $9.119M
YoY Change -7.14% -15.6%
Accrued Expenses $7.337M $6.756M
YoY Change 13.21% 6.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $16.00K $10.00K
YoY Change -20.0% -23.08%
Total Short-Term Liabilities $17.87M $16.73M
YoY Change 1.45% -5.87%
LONG-TERM LIABILITIES
Long-Term Debt $22.00K $0.00
YoY Change -100.0%
Other Long-Term Liabilities $7.494M $7.915M
YoY Change -11.84% 9.6%
Total Long-Term Liabilities $7.516M $7.915M
YoY Change -11.58% 9.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.87M $16.73M
Total Long-Term Liabilities $7.516M $7.915M
Total Liabilities $25.39M $24.64M
YoY Change -2.79% -1.44%
SHAREHOLDERS EQUITY
Retained Earnings -$185.5M -$184.1M
YoY Change 9.79% 12.5%
Common Stock $74.00K $68.00K
YoY Change 8.82% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.67M $21.02M
YoY Change
Total Liabilities & Shareholders Equity $54.06M $45.67M
YoY Change -6.54% -24.46%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$1.418M -$985.0K
YoY Change -73.37% -88.88%
Depreciation, Depletion And Amortization $264.0K $279.0K
YoY Change 0.76% -2.11%
Cash From Operating Activities -$328.0K -$3.740M
YoY Change -93.37% -36.81%
INVESTING ACTIVITIES
Capital Expenditures $172.0K -$52.00K
YoY Change -8700.0% -45.83%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$172.0K -$52.00K
YoY Change 8500.0% -45.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.679M -18.00K
YoY Change 12088.89% -105.31%
NET CHANGE
Cash From Operating Activities -328.0K -3.740M
Cash From Investing Activities -172.0K -52.00K
Cash From Financing Activities 7.679M -18.00K
Net Change In Cash 7.179M -3.810M
YoY Change -247.02% -32.88%
FREE CASH FLOW
Cash From Operating Activities -$328.0K -$3.740M
Capital Expenditures $172.0K -$52.00K
Free Cash Flow -$500.0K -$3.688M
YoY Change -89.88% -36.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14800000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001386570
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Entity File Number
EntityFileNumber
001-37752
dei Entity Registrant Name
EntityRegistrantName
CHROMADEX CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2940963
dei Entity Address Address Line1
EntityAddressAddressLine1
10900 Wilshire Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90024
dei City Area Code
CityAreaCode
310
dei Local Phone Number
LocalPhoneNumber
388-6706
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
CDXC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
74468669 shares
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13262000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28219000 usd
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
51000 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
65000 usd
CY2022Q3 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
2400000 usd
CY2021Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
2100000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4744000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5226000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
15636000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
13601000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4259000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1859000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
37901000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
48905000 usd
CY2022Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2791000 usd
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
3003000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
714000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
857000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3714000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4352000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
545000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
723000 usd
CY2022Q3 us-gaap Assets
Assets
45665000 usd
CY2021Q4 us-gaap Assets
Assets
57840000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9119000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10423000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6756000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6481000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
684000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
528000 usd
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
10000 usd
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
20000 usd
CY2022Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
158000 usd
CY2021Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
161000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16727000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17613000 usd
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4228000 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4346000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3687000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4154000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
24642000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
26113000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68169000 shares
us-gaap Net Income Loss
NetIncomeLoss
-15100000 usd
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68169000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68126000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68126000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
68000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
68000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
205027000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
200614000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-184075000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168953000 usd
CY2022Q3 us-gaap Translation Adjustment Functional To Reporting Currency Net Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
3000 usd
CY2021Q4 us-gaap Translation Adjustment Functional To Reporting Currency Net Of Tax
TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax
-2000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
21023000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31727000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45665000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57840000 usd
CY2022Q3 us-gaap Revenues
Revenues
17063000 usd
CY2021Q3 us-gaap Revenues
Revenues
17308000 usd
us-gaap Revenues
Revenues
51054000 usd
us-gaap Revenues
Revenues
49690000 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
6856000 usd
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
6730000 usd
us-gaap Cost Of Revenue
CostOfRevenue
20273000 usd
us-gaap Cost Of Revenue
CostOfRevenue
19068000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
10207000 usd
CY2021Q3 us-gaap Gross Profit
GrossProfit
10578000 usd
us-gaap Gross Profit
GrossProfit
30781000 usd
us-gaap Gross Profit
GrossProfit
30622000 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5868000 usd
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7221000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
22126000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19711000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1224000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
996000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3547000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2787000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6180000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11202000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22292000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29881000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
13272000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
19419000 usd
us-gaap Operating Expenses
OperatingExpenses
47965000 usd
us-gaap Operating Expenses
OperatingExpenses
52379000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3065000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8841000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-17184000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-21757000 usd
CY2022Q3 cdcx Other Income Net Employee Retention Credit Cares Act
OtherIncomeNetEmployeeRetentionCreditCARESAct
2085000 usd
CY2021Q3 cdcx Other Income Net Employee Retention Credit Cares Act
OtherIncomeNetEmployeeRetentionCreditCARESAct
0 usd
cdcx Other Income Net Employee Retention Credit Cares Act
OtherIncomeNetEmployeeRetentionCreditCARESAct
2085000 usd
cdcx Other Income Net Employee Retention Credit Cares Act
OtherIncomeNetEmployeeRetentionCreditCARESAct
0 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
5000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
15000 usd
us-gaap Interest Expense
InterestExpense
23000 usd
us-gaap Interest Expense
InterestExpense
46000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-985000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-8856000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15122000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21803000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68345000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68345000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68236000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68236000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68331000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68331000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66811000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66811000 shares
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
20778000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1229000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-985000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
21023000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31727000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4413000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
5000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15122000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
21023000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
42142000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
341000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1822000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-8856000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
35449000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
16424000 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
400000 usd
cdcx Issuance Of Common Stock Net Of Offering Costs Amount
IssuanceOfCommonStockNetOfOfferingCostsAmount
26740000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9365000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4722000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21803000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
35449000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15122000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21803000 usd
us-gaap Depreciation
Depreciation
648000 usd
us-gaap Depreciation
Depreciation
679000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
143000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
174000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
638000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
385000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4413000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4722000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-7000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
28000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-152000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-54000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-87000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-454000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
2448000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2035000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
992000 usd
cdcx Implementation Costs For Cloud Computing Arrangement
ImplementationCostsForCloudComputingArrangement
281000 usd
cdcx Implementation Costs For Cloud Computing Arrangement
ImplementationCostsForCloudComputingArrangement
150000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2261000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
608000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1304000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1359000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
275000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
198000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-118000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-95000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-103000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-311000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-472000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14770000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19219000 usd
cdcx Purchases Of Leasehold Improvements And Equipment
PurchasesOfLeaseholdImprovementsAndEquipment
162000 usd
cdcx Purchases Of Leasehold Improvements And Equipment
PurchasesOfLeaseholdImprovementsAndEquipment
407000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-162000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-407000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26740000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9365000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
15000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
47000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
10000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
27000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-25000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36031000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14957000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16405000 usd
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28219000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16697000 usd
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
200000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13262000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33102000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
0 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
372000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
472000 usd
cdcx Right Of Use Assets And Operating Lease Liabilities Incurred Due To Lease Amendment
RightOfUseAssetsAndOperatingLeaseLiabilitiesIncurredDueToLeaseAmendment
0 usd
cdcx Right Of Use Assets And Operating Lease Liabilities Incurred Due To Lease Amendment
RightOfUseAssetsAndOperatingLeaseLiabilitiesIncurredDueToLeaseAmendment
2209000 usd
us-gaap Nature Of Operations
NatureOfOperations
Nature of BusinessChromaDex Corporation and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex International, Inc., ChromaDex Analytics, Inc., ChromaDex Asia Limited, Asia Pacific Scientific, Inc., ChromaDex Europa B.V. and ChromaDex Sağlik Ürünleri Anonim Şirketi (collectively, “ChromaDex” or the “Company”) are a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors. ChromaDex is the innovator behind the NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent and/or licensed rights portfolio. The Company delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen®. The Company further develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. Additionally, the Company offers natural product fine chemicals, known as phytochemicals, and related research and development services.
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13100000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-985000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-8856000 usd
us-gaap Net Income Loss
NetIncomeLoss
-15122000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21803000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68345000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68345000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68236000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68236000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68331000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68331000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66811000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66811000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
748000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
116000 shares
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
748000 shares
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
116000 shares
cdcx Nonvested Shares Of Restricted Stock
NonvestedSharesOfRestrictedStock
200000 shares
CY2021Q3 cdcx Nonvested Shares Of Restricted Stock
NonvestedSharesOfRestrictedStock
200000 shares
cdcx Nonvested Shares Of Restricted Stock
NonvestedSharesOfRestrictedStock
200000 shares
CY2022Q3 cdcx Nonvested Shares Of Restricted Stock
NonvestedSharesOfRestrictedStock
200000 shares
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 reportable_segment
CY2022Q3 us-gaap Revenues
Revenues
17063000 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
6856000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
10207000 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5868000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1224000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6180000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
13272000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3065000 usd
us-gaap Revenues
Revenues
51054000 usd
us-gaap Cost Of Revenue
CostOfRevenue
20273000 usd
us-gaap Gross Profit
GrossProfit
30781000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
22126000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3547000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22292000 usd
us-gaap Operating Expenses
OperatingExpenses
47965000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-17184000 usd
CY2021Q3 us-gaap Revenues
Revenues
17308000 usd
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
6730000 usd
CY2021Q3 us-gaap Gross Profit
GrossProfit
10578000 usd
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7221000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
996000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11202000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
19419000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8841000 usd
us-gaap Revenues
Revenues
49690000 usd
us-gaap Cost Of Revenue
CostOfRevenue
19068000 usd
us-gaap Gross Profit
GrossProfit
30622000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19711000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2787000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29881000 usd
us-gaap Operating Expenses
OperatingExpenses
52379000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-21757000 usd
CY2022Q3 us-gaap Revenues
Revenues
17063000 usd
us-gaap Revenues
Revenues
51054000 usd
CY2021Q3 us-gaap Revenues
Revenues
17308000 usd
us-gaap Revenues
Revenues
49690000 usd
CY2022Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2600000 usd
CY2021Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2600000 usd
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
6700000 usd
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
7100000 usd
CY2022Q3 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
2400000 usd
CY2021Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
2100000 usd
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9214000 usd
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6823000 usd
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
3157000 usd
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
4131000 usd
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
2743000 usd
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2131000 usd
CY2022Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
522000 usd
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
516000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
15636000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
13601000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3700000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4400000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
235000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
152000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
727000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
359000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
47000 usd
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
51000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
132000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
139000 usd
CY2022Q3 cdcx Total Operating Lease Expenses
TotalOperatingLeaseExpenses
282000 usd
CY2021Q3 cdcx Total Operating Lease Expenses
TotalOperatingLeaseExpenses
203000 usd
cdcx Total Operating Lease Expenses
TotalOperatingLeaseExpenses
859000 usd
cdcx Total Operating Lease Expenses
TotalOperatingLeaseExpenses
498000 usd
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
33000 usd
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
63000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
160000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
191000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
315000 usd
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
266000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1019000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
689000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.059
us-gaap Share Based Compensation
ShareBasedCompensation
4413000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
216000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
949000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1159000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1141000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
906000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
498000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
179000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5048000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
677000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4371000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
684000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3687000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.765
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.025
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Price
SharePrice
1.23
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1229000 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1822000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4722000 usd
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6200000 usd
CY2019Q3 us-gaap Accounts Receivable From Securitization
AccountsReceivableFromSecuritization
1600000 usd
CY2022Q3 cdcx Other Income Net Employee Retention Credit Cares Act
OtherIncomeNetEmployeeRetentionCreditCARESAct
2100000 usd

Files In Submission

Name View Source Status
0001628280-22-027803-index-headers.html Edgar Link pending
0001628280-22-027803-index.html Edgar Link pending
0001628280-22-027803.txt Edgar Link pending
0001628280-22-027803-xbrl.zip Edgar Link pending
cdcx-20220930.htm Edgar Link pending
cdcx-20220930.xsd Edgar Link pending
cdcx-20220930_g1.jpg Edgar Link pending
cdxc-amendedandrestateds.htm Edgar Link pending
cdxc-amendedandrestateds001.jpg Edgar Link pending
cdxc-amendedandrestateds002.jpg Edgar Link pending
cdxc-amendedandrestateds003.jpg Edgar Link pending
cdxc-amendedandrestateds004.jpg Edgar Link pending
cdxc-amendedandrestateds005.jpg Edgar Link pending
cdxc-amendedandrestateds006.jpg Edgar Link pending
cdxc-amendedandrestateds007.jpg Edgar Link pending
cdxc-amendedandrestateds008.jpg Edgar Link pending
cdxc-amendedandrestateds009.jpg Edgar Link pending
cdxc-amendedandrestateds010.jpg Edgar Link pending
cdxc-amendedandrestateds011.jpg Edgar Link pending
cdxc-amendedandrestateds012.jpg Edgar Link pending
cdxc-amendedandrestateds013.jpg Edgar Link pending
cdxc-amendedandrestateds014.jpg Edgar Link pending
cdxc-amendedandrestateds015.jpg Edgar Link pending
cdxc-amendedandrestateds016.jpg Edgar Link pending
cdxc-amendedandrestateds017.jpg Edgar Link pending
cdxc-amendedandrestateds018.jpg Edgar Link pending
cdxc-amendedandrestateds019.jpg Edgar Link pending
cdcx-20220930_cal.xml Edgar Link unprocessable
cdcx-20220930_def.xml Edgar Link unprocessable
cdcx-20220930_pre.xml Edgar Link unprocessable
cdcx-20220930_lab.xml Edgar Link unprocessable
cdcx-20220930_htm.xml Edgar Link completed
cdxc-amendedandrestateds020.jpg Edgar Link pending
cdxc-amendedandrestateds021.jpg Edgar Link pending
cdxc-amendedandrestateds022.jpg Edgar Link pending
cdxc-amendedandrestateds023.jpg Edgar Link pending
cdxc-amendedandrestateds024.jpg Edgar Link pending
cdxc-amendedandrestateds025.jpg Edgar Link pending
cdxc-amendedandrestateds026.jpg Edgar Link pending
cdxc-amendedandrestateds027.jpg Edgar Link pending
cdxc-amendedandrestateds028.jpg Edgar Link pending
cdxc-amendedandrestateds029.jpg Edgar Link pending
cdxc-amendedandrestateds030.jpg Edgar Link pending
cdxc-amendedandrestateds031.jpg Edgar Link pending
cdxc-amendedandrestateds032.jpg Edgar Link pending
cdxc-amendedandrestateds033.jpg Edgar Link pending
cdxc-amendedandrestateds034.jpg Edgar Link pending
cdxc-amendedandrestateds035.jpg Edgar Link pending
cdxc-amendedandrestateds036.jpg Edgar Link pending
cdxc-amendedandrestateds037.jpg Edgar Link pending
cdxc-amendedandrestateds038.jpg Edgar Link pending
cdxc-amendedandrestateds039.jpg Edgar Link pending
cdxc-amendedandrestateds040.jpg Edgar Link pending
cdxc-amendedandrestateds041.jpg Edgar Link pending
cdxc-amendedandrestateds042.jpg Edgar Link pending
cdxcq3202210qex-311.htm Edgar Link pending
cdxcq3202210qex-312.htm Edgar Link pending
cdxcq3202210qex-321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable